For someone searching for 'weight loss clinic alpharetta Dr Weight Loss,' geography is an important starting point: Dr. Weight Loss of Atlanta lists its address in Atlanta, GA, rather than Alpharetta. The practice, established around 2016, offers medical weight loss and peptide therapy, placing it within a business category whose national growth projections warrant a closer look—but do not establish the size of the local market.

An Atlanta address anchors Dr. Weight Loss of Atlanta's profile

Dr. Weight Loss of Atlanta is located at 56 East Andrews Dr. Suite 11, Atlanta, GA, 30305. Its approximately 2016 establishment date provides a historical reference point, while its stated service categories identify its business focus: medical weight loss and peptide therapy. Those facts offer a more concrete introduction than a broad regional search label. In particular, the listed address matters when distinguishing a business located in Atlanta from a clinic located in Alpharetta. A search can connect the two place names, but that connection alone is not evidence of an additional office, a particular service territory or a pattern of patient travel. The business profile here is anchored to the Atlanta location supplied in the factual record.

The clinic's website mentions Semaglutide GLP-1 (Ozempic), Tirzepatide, Zepbound, & Mounjaro (GLP-1), Retatrutide (GLP-3), Adipex (Phentermine), HCG (Human Chorionic Gonadotropin), and Tesofensine Peptide. Together with medical weight loss and peptide therapy, these are the named offerings available for describing the business. The list establishes the subjects the website presents; it does not establish how frequently each offering is used, which patients receive it, or what results follow. Likewise, the approximate establishment year should not be stretched into a claim about patient volume, revenue or expansion. A business account can describe the scope of a published menu without treating that menu as evidence of operating scale or clinical outcomes.

Atlanta's obesity estimate and national clinic forecasts measure different things

Two figures help frame the surrounding business story, provided their boundaries remain clear. Grand View Research estimated the national medical weight-loss clinics market at $1.17 billion in 2024 and projected compound annual growth of 4.42% for 2025–2030. Separately, City Health Dashboard reports that an estimated 29.3% of Atlanta adults had obesity in 2023, using CDC PLACES modeled data. The first figure describes a national commercial category; the second describes a modeled health measure for a city. Neither is an Atlanta clinic revenue estimate, and neither supplies an Alpharetta market growth rate. No Atlanta- or Alpharetta-specific clinic market size or growth rate was verified in the supplied market context. That absence is significant: applying the national forecast directly to one municipality would introduce a local conclusion that the available evidence does not support.

For regional business readers, the useful connection is therefore a question of market measurement rather than a claim of inevitable expansion. Atlanta's modeled obesity estimate supplies health context, but it does not count people seeking appointments, paying for treatment or choosing a particular provider. National clinic revenue, meanwhile, cannot show how spending is distributed among local businesses. Broader economic reporting can draw on the U.S. Census Bureau's Business & Economy data resources, while workforce questions can be investigated through U.S. Bureau of Labor Statistics employment and wage resources. Those resources are avenues for additional economic research, not the sources of the clinic-market and obesity figures attributed above. The distinction keeps three separate issues from becoming one unsupported narrative: the prevalence of a health condition, the value of a national service market and the performance of an individual Atlanta practice. Alpharetta search interest adds a geographic question, not proof of local demand or a second business location.

Medical weight loss and peptides define the published service menu

Dr. Weight Loss of Atlanta's stated offerings span medical weight loss, peptide therapy and the individually named items on its website. Its list includes Semaglutide GLP-1 (Ozempic) and Tirzepatide, with Zepbound and Mounjaro also named in the GLP-1 listing. Retatrutide appears as GLP-3, while Adipex is identified as Phentermine and HCG as Human Chorionic Gonadotropin; Tesofensine Peptide is also listed. These names describe the clinic's published service scope. The factual record supplied for this article does not specify prices, appointment schedules, treatment duration, eligibility criteria or results for any listed offering. Accordingly, the service description remains a description of what the business names, rather than a comparison of treatments or an account of individual care. The two overarching categories—medical weight loss and peptide therapy—provide the clearest concise statement of its advertised focus.

The regional business story rests on keeping location, service descriptions and market evidence distinct. Dr. Weight Loss of Atlanta has a stated Atlanta address and an approximately 2016 establishment date; the broader context consists of a national clinic-market estimate and a separate Atlanta health indicator. Those facts support an account of an established business in a defined service category, not a claim about its market share or an Alpharetta footprint. For the business's published information, visit drweightlossofatlanta.com.

Further reading from The Capital Front: Your Skin Transformation’s Aesthetic Treatments Meet a Broader Weight-Loss Search Market and IHC of Charlottesville | Positions Its Weight-Loss Approach in a Changing Market.